BBSRC Portfolio Analyser
Award details
To benchmark the utility of E06: A half-life extension, single-domain, shark antibody bio-tool, and progress it to a Phase 1 ready candidate clone
Reference
BB/K010905/1
Principal Investigator / Supervisor
Professor Andrew Porter
Co-Investigators /
Co-Supervisors
Institution
University of Aberdeen
Department
School of Medical Sciences
Funding type
Research
Value (£)
435,489
Status
Completed
Type
Research Grant
Start date
10/02/2013
End date
09/09/2014
Duration
19 months
Abstract
unavailable
Summary
Scientifically we are developing a "bio-tool" that could be fused to a range of different therapeutic proteins/peptides to extend their serum half-life from hours to weeks, with the potential of greatly increasing their therapeutic potency. It works by hitching a ride on other long-lived proteins in the blood. Commercially, our medium-term goal is to create a Drug Discovery company, based on our unique, single-domain shark antibody (VNAR) platform, which will develop therapeutic agents in-house or in partnership with larger companies. To achieve this, meeting of scientific milestones is key, and in particular confirming non-immunogenicity (not seen by the human immune system & safe for use), and validate the most advanced of our products (E06 VNAR half-life extension bio-tool). Progress towards this goal will also provide a platform for NewCo formation and equity raising, and will deliver an asset capable of securing multiple revenue streams of licensing and partnered income.
Committee
Not funded via Committee
Research Topics
Immunology, Pharmaceuticals
Research Priority
X – Research Priority information not available
Research Initiative
Follow-On Fund Super (SuperFOF) [2012-2015]
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search